Biohaven Ltd. (BHVN) Stock Research

Over a week ago

Biohaven and Yale University awarded $4M in trade secret verdict

BHVN

Jul 27, 7:05 AM

Biohaven enters into clinical supply agreement with Regeneron

Jul 20, 7:34 AM

Biohaven reports new data on BHV-1530

BHVN

Jul 20, 7:33 AM

Biohaven's Bruce Car retires as chief scientific officer

BHVN

Jul 9, 5:01 PM

Biohaven announces completion of enrollment in RISE3 trial

BHVN

Jun 30, 7:31 AM

Biohaven falls -9.8%

BHVN

Jun 29, 10:01 AM

Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves' disease

BHVN

Jun 29, 7:31 AM

Biohaven just downgraded at BofA, here's why

Jun 29, 6:19 AM

Biohaven rises 7.4%

BHVN

Jun 26, 10:00 AM

Biohaven price target raised by $5 at Deutsche Bank, here's why

BHVN

Jun 26, 8:32 AM

Acting FDA head vows to block political interference, Endpoint News says

+23

Jun 4, 2:11 PM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

Biohaven initiates first-in-human dosing for BHV-8100

BHVN

Jun 1, 7:32 AM

Biohaven's candidates in Graves' Disease and IgA nephropathy shows efficacy

BHVN

May 27, 7:38 AM

Biohaven reports data from selective Kv7.2/7.3 channel activator program

BHVN

May 26, 7:36 AM

Biohaven price target lowered by $3 at Morgan Stanley

BHVN

May 13, 8:01 AM

What You Missed On Wall Street On Tuesday

+47

May 12, 4:11 PM

Trump Trade: Trump to suspend tariff-rate quotas on beef imports

+33

May 12, 10:47 AM

Trump approves plan to fire FDA head Marty Makary, CBS reports

+13

May 11, 12:22 PM

Trump Trade: U.S. plans AI security order without required model tests

+17

May 11, 10:09 AM

What You Missed On Wall Street On Friday

+37

May 8, 4:21 PM

Biohaven price target lowered by $1 at RBC Capital, here's why

BHVN

May 5, 8:15 AM

Biohaven price target lowered by $2 at BofA, here's why

BHVN

May 5, 5:51 AM

Biohaven files automatic mixed securities shelf

BHVN

May 4, 4:27 PM

Biohaven reports Q1 adjusted EPS (69c), consensus (76c)

BHVN

May 4, 4:06 PM

Significant Cash Reserves and Financial Flexibility: Having divested their CGRP assets to Pfizer, Biohaven possesses a substantial cash infusion, providing robust financial strength for pipeline development, strategic investments, and potential acquisitions without immediate reliance on dilutive financing.

Specialized Neuroscience and Rare Disease Focus: The company maintains a concentrated research and development strategy in areas of high unmet medical need within neuroscience and rare diseases, leveraging deep expertise and a targeted approach to drug discovery.

Diverse and Advancing Pipeline: Biohaven boasts a pipeline of innovative drug candidates across various stages of development, including assets for epilepsy (Kv7 activators), neuroinflammatory/neurodegenerative diseases (MPO inhibitors), and rare diseases like SCA and PAF.

Clinical Trial Failure or Delay Risk: Biohaven's product candidates may fail to demonstrate efficacy or safety in ongoing or future clinical trials, or these trials may be significantly delayed, preventing or delaying regulatory approval and commercialization.

Regulatory Approval Uncertainty Risk: Even with positive clinical data, Biohaven may not obtain necessary marketing approvals from regulatory authorities like the FDA, or approvals may come with restrictive labels or post-marketing requirements.

Intense Market Competition Risk: Biohaven faces significant competition from larger pharmaceutical companies and other biotechs that may develop superior or more cost-effective treatments for its target indications, eroding potential market share.